Eczacıbaşı-Monrol to expand Lu-177 production

2017 08 16 13 40 50 749 Graph Arrow Up 400

Turkish radiopharmaceutical company Eczacıbaşı-Monrol plans to expand its Lutetium-177 (Lu-177) production capacity.

The company will invest 35 million euros ($37.6 million U.S.) to increase its capacity to produce the radiopharmaceutical at its facility in Gebze, Turkey. Lu-177 is used to treat prostate cancer and neuroendocrine tumors.

Page 1 of 434
Next Page